Lowering Mutant Huntingtin Levels and Toxicity: Autophagy-Endolysosome Pathways in Huntington's Disease
dc.contributor.author | Valionyte, E | |
dc.contributor.author | Yang, Y | |
dc.contributor.author | Roberts, SL | |
dc.contributor.author | Kelly, J | |
dc.contributor.author | Lu, B | |
dc.contributor.author | Luo, S | |
dc.date.accessioned | 2024-05-01T10:30:57Z | |
dc.date.available | 2024-05-01T10:30:57Z | |
dc.date.issued | 2020-04 | |
dc.identifier.issn | 0022-2836 | |
dc.identifier.issn | 1089-8638 | |
dc.identifier.uri | https://pearl.plymouth.ac.uk/handle/10026.1/22376 | |
dc.description.abstract |
Huntington's disease (HD) is a monogenetic neurodegenerative disease, which serves as a model of neurodegeneration with protein aggregation. Autophagy has been suggested to possess a great value to tackle protein aggregation toxicity and neurodegenerative diseases. Current studies suggest that autophagy-endolysosomal pathways are critical for HD pathology. Here we review recent advancement in the studies of autophagy and selective autophagy relating HD. Restoration of autophagy flux and enhancement of selective removal of mutant huntingtin/disease-causing protein would be effective approaches towards tackling HD as well as other similar neurodegenerative disorders. | |
dc.format.extent | 2673-2691 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.publisher | Elsevier BV | |
dc.subject | Autophagy | |
dc.subject | Selective autophagy | |
dc.subject | Huntington's disease | |
dc.subject | Huntingtin | |
dc.subject | Neu rodegeneration | |
dc.title | Lowering Mutant Huntingtin Levels and Toxicity: Autophagy-Endolysosome Pathways in Huntington's Disease | |
dc.type | journal-article | |
dc.type | Review | |
plymouth.author-url | https://www.ncbi.nlm.nih.gov/pubmed/31786267 | |
plymouth.issue | 8 | |
plymouth.volume | 432 | |
plymouth.publisher-url | http://dx.doi.org/10.1016/j.jmb.2019.11.012 | |
plymouth.publication-status | Published | |
plymouth.journal | Journal of Molecular Biology | |
dc.identifier.doi | 10.1016/j.jmb.2019.11.012 | |
plymouth.organisational-group | |Plymouth | |
plymouth.organisational-group | |Plymouth|Research Groups | |
plymouth.organisational-group | |Plymouth|Faculty of Health | |
plymouth.organisational-group | |Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | |Plymouth|Research Groups|Institute of Translational and Stratified Medicine (ITSMED)|CBR | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA | |
plymouth.organisational-group | |Plymouth|Users by role | |
plymouth.organisational-group | |Plymouth|Users by role|Current Academic staff | |
plymouth.organisational-group | |Plymouth|REF 2021 Researchers by UoA|UoA01 Clinical Medicine | |
plymouth.organisational-group | |Plymouth|Faculty of Health|Peninsula Medical School | |
plymouth.organisational-group | |Plymouth|Users by role|Researchers in ResearchFish submission | |
plymouth.organisational-group | |Plymouth|REF 2029 Researchers by UoA | |
plymouth.organisational-group | |Plymouth|REF 2029 Researchers by UoA|UoA01 Clinical Medicine | |
dc.publisher.place | Netherlands | |
dcterms.dateAccepted | 2019-11-19 | |
dc.date.updated | 2024-05-01T10:30:57Z | |
dc.identifier.eissn | 1089-8638 | |
dc.rights.embargoperiod | forever | |
rioxxterms.versionofrecord | 10.1016/j.jmb.2019.11.012 |